Blood Culture Tests Market: Market Size & Forecast 2026

Blood culture testing is a clinical microbiology procedure used to identify circulating microorganisms in a patient's bloodstream, most commonly to diagnose sepsis, endocarditis, and other bloodstream infections. The global market is currently valued at roughly USD 6.7 billion in 2025, placing it among the larger segments of the in-vitro diagnostics industry. Growth is driven by rising sepsis incidence, an aging global population, expanding hospital laboratory capacity, and the gradual shift from manual culture methods to automated continuous-monitoring systems.

• •Estimated 2025 market size of about USD 6.7 billion, with private forecasts spanning roughly USD 11 billion to USD 20 billion by 2030-2035.
• •Used principally for sepsis and bloodstream infection diagnosis in hospital and reference laboratory settings.
• •Automated continuous-monitoring blood culture systems have largely replaced older manual broth-based methods in developed markets.

The principal growth driver is the increasing global burden of sepsis, which the World Health Organization has designated a major public health priority and which accounts for millions of deaths annually. Rising rates of antimicrobial resistance (AMR) are also pushing clinicians and public health authorities to invest in faster, more accurate bloodstream pathogen identification to guide targeted therapy. Expanding healthcare infrastructure in Asia-Pacific, Latin America, and the Middle East is widening patient access to advanced diagnostic testing, while hospital accreditation programs and infection-control mandates are reinforcing routine blood culture utilization.

• •Sepsis incidence is climbing worldwide, with WHO estimating roughly 49 million cases and 11 million deaths each year.
• •Antimicrobial resistance concerns are accelerating demand for rapid pathogen identification and susceptibility testing.
• •Healthcare investment in emerging markets and stricter infection-control regulations are expanding the addressable testing population.

The market is commonly segmented by product (instruments, consumables, and software/services), by test method (conventional/manual culture, automated continuous-monitoring, and molecular blood culture adjuncts), by end user (hospital laboratories, reference laboratories, and academic/research centers), and by pathogen (bacterial, fungal, and mycobacterial). North America currently accounts for the largest regional share, supported by advanced hospital networks and high per-capita testing volumes, while Asia-Pacific is projected to be the fastest-growing region due to healthcare expansion in countries such as China, India, and Japan. Europe represents a mature but steadily growing segment shaped by AMR stewardship programs and universal health coverage.

• •Consumables (culture bottles, media, and reagents) typically make up the largest revenue share due to their recurring use.
• •North America leads in revenue, while Asia-Pacific is the fastest-growing region on a percentage basis.
• •Hospital laboratories remain the dominant end-user segment, with reference lab outsourcing gradually increasing.

What are the recent trends and outlook?

The most prominent trend is the integration of blood culture with rapid molecular diagnostics, such as PCR-based panels and MALDI-TOF mass spectrometry, which can cut pathogen identification time from days to hours after a culture flags positive. Digital laboratory informatics, AI-assisted result interpretation, and the development of direct-from-blood molecular tests that bypass culture entirely are additional directions shaping product roadmaps. With sepsis cases continuing to climb and AMR remaining a top global health concern, the market outlook is for sustained double-digit-style percentage growth through at least the early 2030s, albeit with sizable variation across private-sector forecasts.

• •Rapid molecular identification after a positive culture, plus emerging direct-from-blood molecular assays, are shortening time-to-diagnosis.
• •AI and digital lab informatics are increasingly being layered onto traditional culture workflows to support antimicrobial stewardship.
• •Long-term growth is expected to remain robust, though forecast values diverge widely depending on the research provider's methodology.